EXEL vs. HLN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at EXEL and HLN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
EXEL is a standard domestic listing, while HLN trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | EXEL | HLN |
|---|---|---|
| Company Name | Exelixis, Inc. | Haleon plc |
| Country | United States | United Kingdom |
| GICS Sector | Health Care | Consumer Staples |
| GICS Industry | Biotechnology | Personal Care Products |
| Market Capitalization | 10.36 billion USD | 43.48 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | April 17, 2000 | July 25, 2022 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of EXEL and HLN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | EXEL | HLN |
|---|---|---|
| 5-Day Price Return | 2.94% | 1.98% |
| 13-Week Price Return | 4.08% | -10.35% |
| 26-Week Price Return | 14.32% | -6.08% |
| 52-Week Price Return | 42.93% | -5.03% |
| Month-to-Date Return | 6.27% | -1.25% |
| Year-to-Date Return | 15.59% | -5.94% |
| 10-Day Avg. Volume | 3.51M | 18.28M |
| 3-Month Avg. Volume | 3.38M | 18.67M |
| 3-Month Volatility | 62.34% | 16.25% |
| Beta | 0.36 | 0.35 |
Profitability
Return on Equity (TTM)
EXEL
27.74%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
In the upper quartile for the Biotechnology industry, EXEL’s Return on Equity of 27.74% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
HLN
3.26%
Personal Care Products Industry
- Max
- 31.59%
- Q3
- 20.42%
- Median
- 11.01%
- Q1
- 3.26%
- Min
- -18.42%
HLN’s Return on Equity of 3.26% is on par with the norm for the Personal Care Products industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
EXEL
27.01%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
A Net Profit Margin of 27.01% places EXEL in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
HLN
12.84%
Personal Care Products Industry
- Max
- 15.12%
- Q3
- 12.06%
- Median
- 9.26%
- Q1
- 5.50%
- Min
- -0.40%
A Net Profit Margin of 12.84% places HLN in the upper quartile for the Personal Care Products industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
EXEL
31.38%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
An Operating Profit Margin of 31.38% places EXEL in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
HLN
19.64%
Personal Care Products Industry
- Max
- 19.80%
- Q3
- 17.96%
- Median
- 13.14%
- Q1
- 7.58%
- Min
- -4.25%
An Operating Profit Margin of 19.64% places HLN in the upper quartile for the Personal Care Products industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | EXEL | HLN |
|---|---|---|
| Return on Equity (TTM) | 27.74% | 3.26% |
| Return on Assets (TTM) | 21.09% | 1.58% |
| Net Profit Margin (TTM) | 27.01% | 12.84% |
| Operating Profit Margin (TTM) | 31.38% | 19.64% |
| Gross Profit Margin (TTM) | 96.59% | 60.75% |
Financial Strength
Current Ratio (MRQ)
EXEL
3.51
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
EXEL’s Current Ratio of 3.51 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
HLN
0.87
Personal Care Products Industry
- Max
- 4.26
- Q3
- 2.61
- Median
- 1.74
- Q1
- 1.13
- Min
- 0.76
HLN’s Current Ratio of 0.87 falls into the lower quartile for the Personal Care Products industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
EXEL
0.00
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
EXEL’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
HLN
0.53
Personal Care Products Industry
- Max
- 1.13
- Q3
- 0.63
- Median
- 0.26
- Q1
- 0.04
- Min
- 0.00
HLN’s Debt-to-Equity Ratio of 0.53 is typical for the Personal Care Products industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
EXEL
42.74
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
EXEL’s Interest Coverage Ratio of 42.74 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
HLN
8.00
Personal Care Products Industry
- Max
- 96.53
- Q3
- 59.91
- Median
- 22.25
- Q1
- 7.85
- Min
- -1.93
HLN’s Interest Coverage Ratio of 8.00 is positioned comfortably within the norm for the Personal Care Products industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | EXEL | HLN |
|---|---|---|
| Current Ratio (MRQ) | 3.51 | 0.87 |
| Quick Ratio (MRQ) | 3.22 | 0.63 |
| Debt-to-Equity Ratio (MRQ) | 0.00 | 0.53 |
| Interest Coverage Ratio (TTM) | 42.74 | 8.00 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
EXEL
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXEL currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
HLN
0.72%
Personal Care Products Industry
- Max
- 4.08%
- Q3
- 2.46%
- Median
- 1.82%
- Q1
- 0.83%
- Min
- 0.00%
HLN’s Dividend Yield of 0.72% is in the lower quartile for the Personal Care Products industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.
Dividend Payout Ratio (TTM)
EXEL
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXEL has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
HLN
954.40%
Personal Care Products Industry
- Max
- 207.61%
- Q3
- 115.17%
- Median
- 69.37%
- Q1
- 47.71%
- Min
- 0.00%
At 954.40%, HLN’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Personal Care Products industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
Dividend at a Glance
| Symbol | EXEL | HLN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.72% |
| Dividend Payout Ratio (TTM) | 0.00% | 954.40% |
Valuation
Price-to-Earnings Ratio (TTM)
EXEL
17.18
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
EXEL’s P/E Ratio of 17.18 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
HLN
22.09
Personal Care Products Industry
- Max
- 55.49
- Q3
- 36.75
- Median
- 26.49
- Q1
- 22.40
- Min
- 11.12
In the lower quartile for the Personal Care Products industry, HLN’s P/E Ratio of 22.09 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
EXEL
4.64
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
EXEL’s P/S Ratio of 4.64 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
HLN
2.84
Personal Care Products Industry
- Max
- 5.35
- Q3
- 2.83
- Median
- 2.07
- Q1
- 1.13
- Min
- 0.00
HLN’s P/S Ratio of 2.84 is in the upper echelon for the Personal Care Products industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
EXEL
6.19
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
EXEL’s P/B Ratio of 6.19 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
HLN
2.11
Personal Care Products Industry
- Max
- 7.32
- Q3
- 5.26
- Median
- 2.93
- Q1
- 1.84
- Min
- 1.14
HLN’s P/B Ratio of 2.11 is within the conventional range for the Personal Care Products industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | EXEL | HLN |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 17.18 | 22.09 |
| Price-to-Sales Ratio (TTM) | 4.64 | 2.84 |
| Price-to-Book Ratio (MRQ) | 6.19 | 2.11 |
| Price-to-Free Cash Flow Ratio (TTM) | 13.72 | 14.81 |